200 related articles for article (PubMed ID: 25158020)
1. Sjögren's syndome and extragonadal sex steroid formation: a clue to a better disease control?
Konttinen YT; Stegajev V; Al-Samadi A; Porola P; Hietanen J; Ainola M
J Steroid Biochem Mol Biol; 2015 Jan; 145():237-44. PubMed ID: 25158020
[TBL] [Abstract][Full Text] [Related]
2. Androgen deficiency and defective intracrine processing of dehydroepiandrosterone in salivary glands in Sjögren's syndrome.
Porola P; Virkki L; Przybyla BD; Laine M; Patterson TA; Pihakari A; Konttinen YT
J Rheumatol; 2008 Nov; 35(11):2229-35. PubMed ID: 18843777
[TBL] [Abstract][Full Text] [Related]
3. Activation of plasmacytoid dendritic cells by apoptotic particles - mechanism for the loss of immunological tolerance in Sjögren's syndrome.
Ainola M; Porola P; Takakubo Y; Przybyla B; Kouri VP; Tolvanen TA; Hänninen A; Nordström DC
Clin Exp Immunol; 2018 Mar; 191(3):301-310. PubMed ID: 29105068
[TBL] [Abstract][Full Text] [Related]
4. Failure of oral DHEA treatment to increase local salivary androgen outputs of female patients with Sjögren's syndrome.
Porola P; Straub RH; Virkki LM; Konttinen YT; Nordström DC
Scand J Rheumatol; 2011; 40(5):387-90. PubMed ID: 21877998
[TBL] [Abstract][Full Text] [Related]
5. Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations.
Forsblad-d'Elia H; Carlsten H; Labrie F; Konttinen YT; Ohlsson C
J Clin Endocrinol Metab; 2009 Jun; 94(6):2044-51. PubMed ID: 19318446
[TBL] [Abstract][Full Text] [Related]
6. Sex steroids in Sjögren's syndrome.
Konttinen YT; Fuellen G; Bing Y; Porola P; Stegaev V; Trokovic N; Falk SS; Liu Y; Szodoray P; Takakubo Y
J Autoimmun; 2012 Aug; 39(1-2):49-56. PubMed ID: 22300712
[TBL] [Abstract][Full Text] [Related]
7. Sex steroid hormones in primary Sjögren's syndrome.
Brennan MT; Sankar V; Leakan RA; Grisius MM; Collins MT; Fox PC; Baum BJ; Pillemer SR
J Rheumatol; 2003 Jun; 30(6):1267-71. PubMed ID: 12784401
[TBL] [Abstract][Full Text] [Related]
8. The influence of sex steroids on Sjögren's syndrome.
Porola P; Laine M; Virkki L; Poduval P; Konttinen YT
Ann N Y Acad Sci; 2007 Jun; 1108():426-32. PubMed ID: 17894007
[TBL] [Abstract][Full Text] [Related]
9. Healthy human salivary glands contain a DHEA-sulphate processing intracrine machinery, which is deranged in primary Sjögren's syndrome.
Spaan M; Porola P; Laine M; Rozman B; Azuma M; Konttinen YT
J Cell Mol Med; 2009 Jul; 13(7):1261-70. PubMed ID: 19298523
[TBL] [Abstract][Full Text] [Related]
10. The complexity of Sjögren's syndrome: novel aspects on pathogenesis.
Jonsson R; Vogelsang P; Volchenkov R; Espinosa A; Wahren-Herlenius M; Appel S
Immunol Lett; 2011 Dec; 141(1):1-9. PubMed ID: 21777618
[TBL] [Abstract][Full Text] [Related]
11. Low salivary dehydroepiandrosterone and androgen-regulated cysteine-rich secretory protein 3 levels in Sjögren's syndrome.
Laine M; Porola P; Udby L; Kjeldsen L; Cowland JB; Borregaard N; Hietanen J; Ståhle M; Pihakari A; Konttinen YT
Arthritis Rheum; 2007 Aug; 56(8):2575-84. PubMed ID: 17665393
[TBL] [Abstract][Full Text] [Related]
12. Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate.
Bombardieri M; Barone F; Pittoni V; Alessandri C; Conigliaro P; Blades MC; Priori R; McInnes IB; Valesini G; Pitzalis C
Arthritis Res Ther; 2004; 6(5):R447-56. PubMed ID: 15380044
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic targets in estrogen deficiency-dependent Sjögren's syndrome-related manifestations.
Arakaki R; Ishimaru N; Hayashi Y
Immunotherapy; 2010 May; 2(3):339-46. PubMed ID: 20635899
[TBL] [Abstract][Full Text] [Related]
14. Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA-deficient patients with primary Sjögren's syndrome.
Virkki LM; Porola P; Forsblad-d'Elia H; Valtysdottir S; Solovieva SA; Konttinen YT
Arthritis Care Res (Hoboken); 2010 Jan; 62(1):118-24. PubMed ID: 20191499
[TBL] [Abstract][Full Text] [Related]
15. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism.
Båve U; Nordmark G; Lövgren T; Rönnelid J; Cajander S; Eloranta ML; Alm GV; Rönnblom L
Arthritis Rheum; 2005 Apr; 52(4):1185-95. PubMed ID: 15818675
[TBL] [Abstract][Full Text] [Related]
16. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause.
Labrie F
J Steroid Biochem Mol Biol; 2015 Jan; 145():133-8. PubMed ID: 24923731
[TBL] [Abstract][Full Text] [Related]
17. Histopathological and immunohistochemical analysis of lymphoid follicles in labial salivary glands in primary and secondary Sjögren's syndrome.
Prochorec-Sobieszek M; Wagner T; Loukas M; Chwalińska-Sadowska H; Olesińska M
Med Sci Monit; 2004 Apr; 10(4):BR115-21. PubMed ID: 15039641
[TBL] [Abstract][Full Text] [Related]
18. Endocrine alterations in primary Sjogren's syndrome: an overview.
Mavragani CP; Fragoulis GE; Moutsopoulos HM
J Autoimmun; 2012 Dec; 39(4):354-8. PubMed ID: 22695186
[TBL] [Abstract][Full Text] [Related]
19. The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjögren's syndrome: a critical review.
Sumida T; Tsuboi H; Iizuka M; Hirota T; Asashima H; Matsumoto I
J Autoimmun; 2014 Jun; 51():44-50. PubMed ID: 24397962
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Disease: primary Sjögren's syndrome and the type I interferon system.
Nordmark G; Alm GV; Rönnblom L
Nat Clin Pract Rheumatol; 2006 May; 2(5):262-9. PubMed ID: 16932699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
